Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 6;9(1):12856.
doi: 10.1038/s41598-019-49329-0.

Clinical Model for Predicting Warfarin Sensitivity

Zhiyuan Ma  1   2 , Gang Cheng  3 , Ping Wang  4 , Bahar Khalighi  5 , Koroush Khalighi  6   7   8   9
Affiliations

Clinical Model for Predicting Warfarin Sensitivity

Zhiyuan Ma et al. Sci Rep. .

Abstract

Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the therapeutic dose. Complications from inappropriate warfarin dosing are one of the most common reasons for emergency room visits. Approximately one third of warfarin dose variability results from common genetic variants. Therefore, it is very necessary to recognize warfarin sensitivity in individuals caused by genetic variants. Based on combined polymorphisms in CYP2C9 and VKORC1, we established a clinical classification for warfarin sensitivity. In the International Warfarin Pharmacogenetic Consortium (IWPC) with 5542 patients, we found that 95.1% of the Black in the IWPC cohort were normal warfarin responders, while 74.8% of the Asian were warfarin sensitive (P < 0.001). Moreover, we created a clinical algorithm to predict warfarin sensitivity in individual patients using logistic regression. Compared to a fixed-dose approach, the clinical algorithm provided significantly better performance. In addition, we validated the derived clinical algorithm using the external Easton cohort with 106 chronic warfarin users. The AUC was 0.836 vs. 0.867 for the Easton cohort and the IWPC cohort, respectively. With the use of this algorithm, it is very likely to facilitate patient care regarding warfarin therapy, thereby improving clinical outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Warfarin stable dose across different genotypes. N: normal; S: sensitive; VS: very sensitive.
Figure 2
Figure 2
ROC curve analysis of the IWPC and Easton cohorts using the warfarin sensitivity algorithm.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Johnson JA. Warfarin pharmacogenetics: a rising tide for its clinical value. Circulation. 2012;125:1964–1966. doi: 10.1161/CIRCULATIONAHA.112.100628. - DOI - PMC - PubMed
    1. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in Ambulatory Oral Anticoagulant Use. Am J Med. 2015;128:1300–1305 e1302. doi: 10.1016/j.amjmed.2015.05.044. - DOI - PMC - PubMed
    1. Shaw K, et al. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Ther Drug Monit. 2015;37:428–436. doi: 10.1097/FTD.0000000000000192. - DOI - PubMed
    1. D’Andrea G, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105:645–649. doi: 10.1182/blood-2004-06-2111. - DOI - PubMed
    1. Rieder MJ, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285–2293. doi: 10.1056/NEJMoa044503. - DOI - PubMed

MeSH terms

Supplementary concepts